Empliciti Package Insert

Elotuzumab - Wikipedia
Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma. The package insert denotes its mechanism as a SLAMF7 -directed (also known as CD 319) immunostimulatory antibody. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION ABRAXANE
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer- , in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ... Retrieve Content

Medical Department Procedure Manual - Home - AvMed
3.1 Medical Department staff has access to the Medical Department Procedure Manual and receives notice from management when procedures are developed, updated and/or revised, or archived. Empliciti [package insert]. Princeton, NJ; Janssen Biotech, Inc. November 2015. 2. NCCN Guidelines for ... Visit Document

*Sections Or Subsections Omitted From The Full Prescribing ...
3 of 13 partners of reproductive potential during therapy and for 3 months after the final dose of ERIVEDGE. Advise pregnant women of the potential risk to a fetus [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)]. ... Return Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
Page 3 of 35 FULL PRESCRIBING INFORMATION WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY • Left Ventricular Dysfunction: PERJETA can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. ... Return Document

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
On days that Empliciti is administered, dexamethasone should be given as 28 mg orally once daily between 3 and 24 hours before Empliciti plus 8 mg intravenously between 45 and 90 minutes before Empliciti on days 1, 8, 15, and 22 of repeated 28-day cycles. ... Return Document

Last Review Status/Date - Media.fepblue.org
Effectiveness of Empliciti have not been established in pediatric patients (1). Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Empliciti while maintaining optimal therapeutic outcomes. References . 1. Empliciti [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. May 2017. Policy ... Read Document

HIGHLIGHTS OF PRESCRIBING INFORMATION - Merck.com
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZOLINZA® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ... Retrieve Full Source

Empliciti (elotuzumab) - Caremark.com
Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Compendial Use Empliciti [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; May 2017. ... Return Document

Page 1 Of 24 - Ninlarohcp.com
Page 1 of 24 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use NINLARO safely and effectively. ... Retrieve Document

Page 1 Of 23
The most common adverse reactions ( -----Page 1 of 23 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ... Read Full Source

Empliciti (elotuzumab) - Magellan Provider
Empliciti ™ (elotuzumab) Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for elotuzumab. National Comprehensive Cancer Network, 2017. ... Fetch Content

EMPLICITI (elotuzumab) - Caremark
EMPLICITI (elotuzumab) Empliciti FEP Clinical Rationale RATIONALE FOR INCLUSION IN PA PROGRAM Background Empliciti is a monoclonal antibody that specifically targets the SLAMF7 protein. Multiple myeloma is a cancer that forms in a type of white blood cell called plasma cells. SLAMF7 protein is expressed on both myeloma and natural killer cells. ... Return Document

THALOMID (thalidomide) Capsules - HemOnc.org
THALOMID® (thalidomide) Capsules 50 mg, 100 mg, 150 mg & 200 mg DESCRIPTION THALOMID® (thalidomide), α-(N-phthalimido) glutarimide, is an immunomodulatory agent. The empirical formula for thalidomide is C13H10N2O4 and the gram molecular weight is 258.2. The CAS number of thalidomide is 50-35-1. Chemical Structure of thalidomide ... Retrieve Document

HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Retrieve Doc

Empliciti (elotuzumab) - Moda Health
Empliciti 300 mg single-dose vial: 00003-2291-xx Empliciti 400 mg single-dose vial: 00003-4522-xx VII. References 1. Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for elotuzumab. ... Fetch Full Source

Empliciti (elotuzumab) - Magellan Provider
Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2017. Accessed October 2017. Empliciti™ (elotuzumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ... Retrieve Doc

Last Review Status/Date - FEP Blue
Empliciti has been shown to cause hepatotoxicity and should be stopped if Grade 3 or higher of liver enzymes and therapy continued after return to baseline. Safety and Empliciti [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. November 2015. ... Doc Viewer

Reference ID: 3366104 - ZEVALIN
6. Transfer 1.3 mL of Zevalin (ibritumomab tiuxetan) to the reaction vial. Do not shake or agitate the vial contents. 7. Allow the labeling reaction to proceed at room temperature for 5 minutes. A shorter or longer reaction time may adversely alter the final labeled product. 8. ... Read More

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Ovarian Cancer GEMZAR®in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ... Get Content Here

LEUCOVORIN CALCIUM FOR INJECTION - HemOnc.org
LEUCOVORIN CALCIUM FOR INJECTION Rx only DESCRIPTION Leucovorin is one of several active, chemically reduced derivatives of folic acid. It is useful ... Fetch Content